Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4583222 | 0.90 | TDP1 (0.51) | NPC1RAB9ASMN1; SMN2MAPTMEN1 | |
| SCHEMBL4797029 | 0.82 | MAPT (0.47) | MAPTMEN1KMT2A | |
| SCHEMBL4798159 | 0.76 | P4HB (0.51) | — | |
| SCHEMBL4796301 | 0.74 | TGM2 (0.50) | NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL4778439 | 0.73 | MAOA (0.51) | SMN1; SMN2MAPTMEN1KMT2ATDP1 | |
| SCHEMBL4781996 | 0.72 | AR (0.43) | — | |
| SCHEMBL4782629 | 0.72 | MAOA (0.46) | SMN1; SMN2MAPTMEN1KMT2ATDP1 | |
| SCHEMBL4780631 | 0.71 | MAOA (0.49) | SMN1; SMN2MAPTMEN1KMT2ATDP1 | |
| SCHEMBL4795882 | 0.69 | MAP3K7 (0.56) | SMN1; SMN2MAPTMEN1KMT2ATDP1 | |
| SCHEMBL4782134 | 0.69 | MAP3K7 (0.56) | MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008015265-A1 | ANTHRACEN DERIVATIVES AND THEIR USE FOR THE TREATMENT OF BENIGN AND MALIGNANT TUMOROUS DISEASES | ÆTERNA ZENTARIS GMBH (DE) | 2008-02-07 | — | — | WO | disclosed |